CSPC Pharmaceutical Group (01093.HK): Phase I/II clinical trial of SYS6043 for the treatment of advanced solid tumors officially launched at the first site in China

Zhitong Finance APP News, CSPC Pharmaceutical Group (01093.HK) announced that an open-label, multicenter Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of its developed SYS6043 (B7-H3-ADC) as monotherapy or in combination with bevacizumab and/or chemotherapy in participants with advanced solid tumors has officially been initiated at the first site in China.